贝伐单抗靶向治疗结直肠癌的临床疗效

赵慧芝

（山西省晋中市第二人民医院肿瘤科，山西 晋中，030800）

浏览次数：221次 下载次数：400次

摘要：

目的 探究贝伐单抗靶向治疗结直肠癌的临床效果。方法 从2015年7月至2016年7月我院收治的结直肠癌患者中选取 74 例患者，按照入院先后顺序分为对照组（n=37）和观察组（n=37），对照组患者采用卡培他滨联合奥沙利铂治疗，观察组在此基 础上采用贝伐单抗治疗。通过比较两组患者的治疗总有效率，治疗前、后肿瘤标志物水平和KPS 评分及毒副反应发生情况评估 两组患者的临床疗效。结果 观察组治疗总有效率高于对照组（P<0.05）；治疗后两组患者的CA19-9、CEA、CA242 水平及KPS 评 分均改善，观察组CA19-9、CEA、CA242 水平低于对照组，KPS 评分显著高于对照组（P<0.05）；两组毒副反应总发生率无明显 差异（P>0.05）。结论 贝伐单抗靶向治疗结直肠癌疗效确切，有利于降低肿瘤标志物水平，毒副作用轻微，患者可耐受。

关键词：结直肠癌；贝伐单抗；靶向治疗

中图分类号：R735.3文献标志码：A文章编号：2096-1413(2017)35-0014-02

Clinical effect of bevacizumab in the targeted treatment of colorectal cancer
ZHAO Hui-zhi
(Oncology Department, the Second People``s Hospital of Jinzhong, Jinzhong 030800, China)

ABSTRACT: Objective To explore the clinical effect of bevacizumab in the targeted treatment of colorectal cancer. Methods Seventy-four cases of patients with colorectal cancer admitted from July 2015 to July 2016 in our hospital were selected, and divided into control group (n=37) and observation group (n=37) according to admission order. The control group was treated with capecitabine plus oxaliplatin; on this basis, the observation group was treated with bevacizumab. The clinical effects of the two groups were evaluated by total effective rate, tumor marker levels and KPS scores before and after treatment and adverse reactions. Results The total effective rate in the observation group was higher than that in the control group (P<0.05). The levels of CA19-9, CEA and CA242, KPS scores in both groups significantly improved (P<0.05); compared with the control group, the levels of CA19-9, CEA and CA242 in the observation group were lower, and the KPS score was significantly higher (P<0.05). There was no significant difference in the total incidence rate of adverse reactions between the two groups (P>0.05). Conclusion Bevacizumab is effective in the treatment of colorectal cancer, which is beneficial to reduce the level of tumor markers, and has mild side effects.
KEYWORDS: colorectal cancer; bevacizumab; targeted therapy

参考文献：
[1] 张路昌,潘京胜.探讨贝伐单抗联合伊立替康治疗晚期结直肠癌的临床疗效[J].医药前沿,2015,5(15):61-62.
[2] 余文昌,张孔志,陈示光,等.实体瘤反应评价标准、欧洲肝病学会和改良实体瘤反应评价标准评价原发性肝癌化疗栓塞效果一致性的 比较[J].中华放射学杂志,2011,45(8):766-769.
[3] 啜东宇.贝伐单抗在结直肠癌靶向治疗中的临床应用[J].中国现代 药物应用,2013,7(7):55-56.
[4] 房智慧,马会芳,张凯,等.贝伐单抗联合XELOX 方案治疗晚期结直肠癌的临床观察[J].实用医学杂志,2013,29(23):3928-3930.
[5] 张骥杰,倪国华,吴书庆,等.贝伐单抗联合IFL 方案治疗晚期结肠 癌的临床研究[J].江苏医药,2014,40(19):2331-2333.
[6] 张再军,杜宇.贝伐单抗联合化疗用于晚期结直肠癌临床观察[J]. 中国医药指南,2011,9(8):190-191.
[7] 赵静,张文,李文桦,等.贝伐单抗联合化疗治疗晚期结直肠癌的临 床观察[J].中国癌症杂志,2011,21(10):799-802.
[8] 张军,彭碧文,王亚萍,等.贝伐单抗靶向治疗结直肠癌的安全性和 有效性分析[J].实用临床医药杂志,2013,17(16):90-91,96.